TTUHSC Preston Smith Library presents

Pharmacy Information Resources

PubMed Database

Biomedical journal literature



International scope



Published by:

The National Library of Medicine



Accessing PubMed

Freely available over the Internet



@ www.pubmed.gov



Also through library's home page



Evidence-Based Practice is guided by thoughtful integration






of the best available scientific knowledge with clinical expertise.

PubMed's Clinical Queries

tool that searches for evidence-based literature




Clinical Queries Searchable by:










Clinical Queries Searchable by:










PubMed's Clinical Queries

uses pre-formulated search strategies with a keyword search


Category Optimized For Specific Specific PubMed Equivalent	Clinical Queries using Research Methodology Filters										
therapy therapy therapy sensitive/broad 99%/70% OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) specific/narrow 93%/97% (randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] AND controlled[Title/Abstract] AND trial[Title/Abstract])) sensitive/broad 98%/74% (sensitiv*[Title/Abstract] OR sensitivity and specificity[MeSH Terms] OR diagnos* [Title/Abstract] OR diagnosis[MeSH:noexp] OR diagnosic* *[MeSH:noexp] OR diagnosis[Subheading:noexp])) specific/narrow 64%/98% (specificity[Title/Abstract]) sensitive/broad 93%/63% (risk*[Title/Abstract] OR risk*[MeSH:noexp] OR risk*[MeSH:noexp] OR cohort studies[MeSH Terms] OR group*[Text Word]) etiology specific/narrow 51%/95% (relative[Title/Abstract] AND risk*[Title/Abstract]) OR (relative risk[Text Word]) OR risks[Text Word] OR cohort studies[MeSH:noexp] OR mortality[MeSH Terms] OR follow up studies[MeSH:noexp] OR prognos*[Text Word] OR course*[Text Word]) specific/narrow 52%/94% clinical prediction sensitive/broad 96%/79% OR colort[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract]) OR cohort[Title/Abstract]) OR cohort[Title/Abstract] OR observ*[tiab] OR observ*[tiab] OR observer variation[mh])	Category	Optimized For		PubMed Equivalent							
specific/narrow 93%/97% controlled[Title/Abstract] AND trial[Title/Abstract])) diagnosis sensitive/broad 98%/74% (sensitiv*[Title/Abstract] OR sensitivity and specificity[MeSH Terms] OR diagnos* [Title/Abstract] OR diagnosis[MeSH:noexp] OR diagnostic * [MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR diagnosis[Subheading:noexp]) specific/narrow 64%/98% (specificity[Title/Abstract]) sensitive/broad 93%/63% (risk*[Title/Abstract] OR risk*[MeSH:noexp] OR risk *[MeSH:noexp] OR cohort studies[MeSH Terms] OR group*[Text Word]) specific/narrow 51%/95% (risk*[Title/Abstract] AND risk*[Title/Abstract]) OR (relative risk[Text Word]) OR risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND stud*[Title/Abstract])) sensitive/broad 90%/80% (incidence[MeSH:noexp] OR mortality[MeSH Terms] OR follow up studies[MeSH:noexp] OR prognos*[Text Word] OR course*[Text Word] OR course*[Text Word] OR course*[Text Word]) clinical prediction 96%/79% (prognos*[Title/Abstract] AND episode[Title/Abstract]) OR observ*[tiab] OR observer variation[mh])	therapy	sensitive/broad	99%/70%	OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random							
diagnosis sensitive/broad g8%/74% [Title/Abstract] OR diagnosis[MeSH:noexp] OR diagnostic * [MeSH:noexp] OR diagnosis[Subheading:noexp]) specific/narrow 64%/98% sensitive/broad g3%/63% etiology specific/narrow 51%/95% sensitive/broad prognosis sensitive/broad g8%/74% [Title/Abstract] OR diagnosis[MeSH:noexp] OR diagnosic * [MeSH:noexp] OR diagnosis[Subheading:noexp]) (specificity[Title/Abstract]) (risk*[Title/Abstract] OR risk*[MeSH:noexp] OR risk * [MeSH:noexp] OR cohort studies[MeSH Terms] OR group*[Text Word]) ((relative[Title/Abstract] AND risk*[Title/Abstract]) OR (relative risk[Text Word]) OR risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND stud*[Title/Abstract])) (incidence[MeSH:noexp] OR mortality[MeSH Terms] OR follow up studies[MeSH:noexp] OR prognos*[Text Word] OR predict*[Text Word] OR course*[Text Word]) specific/narrow 52%/94% (prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract]) clinical prediction sensitive/broad g6%/79% (predict*[tiab] OR predictive value of tests[mh] OR scor*[tiab] OR observ*[tiab] OR observer variation[mh])		specific/narrow	93%/97%								
sensitive/broad 93%/63% (risk*[Title/Abstract] OR risk*[MeSH:noexp] OR risk *[MeSH:noexp] OR cohort studies[MeSH Terms] OR group*[Text Word]) specific/narrow 51%/95% ((relative[Title/Abstract] AND risk*[Title/Abstract]) OR (relative risk[Text Word]) OR risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND stud*[Title/Abstract])) sensitive/broad 90%/80% (incidence[MeSH:noexp] OR mortality[MeSH Terms] OR follow up studies[MeSH:noexp] OR prognos*[Text Word] OR prognos*[Text Word]) specific/narrow 52%/94% (prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract]) clinical prediction 96%/79% (predict*[tiab] OR predictive value of tests[mh] OR scor*[tiab] OR observ*[tiab] OR observer variation[mh])	diagnosis	sensitive/broad	98%/74%	[Title/Abstract] OR diagnosis[MeSH:noexp] OR diagnostic * [MeSH:noexp] OR							
sensitive/broad 93%/63% studies[MeSH Terms] OR group*[Text Word]) ((relative[Title/Abstract] AND risk*[Title/Abstract]) OR (relative risk[Text Word]) OR risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND stud*[Title/Abstract])) sensitive/broad prognosis prognosis sensitive/broad prognos* (prognos*[Title/Abstract] OR first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract] OR (first[Title/Abstract]) OR cohort[Title/Abstract]) clinical prediction sensitive/broad prognos 96%/79% (predict*[tiab] OR predictive value of tests[mh] OR scor*[tiab] OR observ*[tiab] OR observer variation[mh])		specific/narrow	64%/98%	(specificity[Title/Abstract])							
specific/narrow 51%/95% risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND stud*[Title/Abstract])) sensitive/broad prognosis specific/narrow 52%/94% (prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract] OR (first[Title/Abstract] OR cohort[Title/Abstract]) OR cohort[Title/Abstract]) clinical prediction 96%/79% (predict*[tiab] OR predictive value of tests[mh] OR scor*[tiab] OR observ*[tiab] OR observer variation[mh])		sensitive/broad	93%/63%								
sensitive/broad 90%/80% studies[MeSH:noexp] OR prognos*[Text Word] OR predict*[Text Word] OR course*[Text Word]) specific/narrow 52%/94% (prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract]) clinical prediction 96%/79% (predict*[tiab] OR predictive value of tests[mh] OR scor*[tiab] OR observ*[tiab] OR observer variation[mh])	etiology	specific/narrow	51%/95%	risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND							
cohort[Title/Abstract]) clinical prediction sensitive/broad prediction clinical prediction clinical prediction clinical prediction sensitive/broad predictive/broad predictive/broad prediction clinical prediction clinical predictive/broad predictive/broad predictive/broad prediction clinical prediction cohort[Title/Abstract]) cohort[Title/Abstract]) cohort[Title/Abstract])	prognosis	sensitive/broad	90%/80%	studies[MeSH:noexp] OR prognos*[Text Word] OR predict*[Text Word] OR							
prediction sensitive/broad 96%/79% observer variation[mh])		specific/narrow	52%/94%								
guides specific/narrow 54%/99% (validation[tiab] OR validate[tiab])		sensitive/broad	96%/79%								
1	guides	specific/narrow	54%/99%	(validation[tiab] OR validate[tiab])							

www.ttuhsc.edu/libraries



Mouse over Databases

Click PubMed



Click Clinical Queries

Enter asthma

My NCBI Sign In

Desk

PubMed Clinical Queries

to specific clinical research areas. For comprehensive searches, use PubMed directly. Results of searches on this

asthma

Clinical Study Categories

This column displays citations filtered to a specific clinical study category and scope. These search filters were developed by Haynes RB et al. See more filter information.

Systematic Reviews

This column displays citations for systematic reviews, meta-analyses, reviews of clinical trials, evidencebased medicine, consensus development conferences, and guidelines. See filter information or additional related sources.

Medical Genetics

This column displays citatio gining to topics in medical genetics. See more rmation.

Search

You are here: NCBI > Literature > PubMed

GETTING STARTED

NCBI Education

NCBI Help Manual

NCBI Handbook

Training & Tutorials

RESOURCES

Chemicals & Bioassays

Data & Software

DNA & RNA

Domains & Structures

Genes & Expression

Genetics & Medicine

Genomes & Maps

Homology

Literature

Proteins

Sequence Analysis

Taxonomy

Training & Tutorials

Variation

POPULAR

PubMed

Nucleotide

BLAST

PubMed Central

Gene

Bookshelf

Protein

OMIM

Genome

SNP

Structure

Click Search

Influenza Virus

Primer-BLAST

Sequence Read Archive

PubMed Clinical Queries

Results of searches on this page are limited to specific clinical research areas. For comp

asthma

Clinical Study Categories

Category: Therapy

Scope: Broad

Results: 5 of 55797

Psychosocial group intervention to enhance selfmanagement skills of people with dementia and their caregivers: study protocol for a randomized controlled trial.

Laakkonen ML, Hölttä EH, Savikko N, Strandberg TE, Suominen M, Pitkälä KH.

Trials. 2012 Aug 7; 13(1):133. Epub 2012 Aug 7.

[Clinical effects of budesonide/formoterol combination drug in elder patients with asthma compared with budesonide plus tulobuterol patch combination treatment].

Onari Y, Haruta Y, Mukaida K, Kondoh K. Arerugi, 2012 Jun; 61(6):820-31.

Feasibility of exercising adults with asthma: a randomized pilot study.

Boyd A, Yang CT, Estelle K, Tuggle C, Gerald LB, Dransfield M, Bamman M, Bonner J, Atkinson TP, Schwiebert LM.

Allergy Asthma Clin Immunol. 2012 Aug 3; 8(1):13. Epub 2012 Aug 3.

Effects of Ionized Waterfall Aerosol on Pediatric Allergic Asthma.

Gaisberger M, Sanović R, Dobias H, Kolarž P, Moder A, Thalhamer J, Selimović A, Huttegger I, Ritter M. Hartl A.

J Asthma. 2012 Aug 6; . Epub 2012 Aug 6.

Effectiveness of magnesium sulfate as initial treatment of acute severe asthma in children, conducted in a tertiary-level university hospital: A randomized. controlled trial.

Torres S, Sticco N, Bosch JJ, Iolster T, Siaba A, Rocca Rivarola M, Schnitzler E.

Arch Argent Pediatr. 2012 Aug; 110(4):291-6.

See all (55797)

This column displays citations filtered to a specific clinical study category and scope. These search filters were developed by <u>Haynes RB et al.</u> See more filter information.

Results for Therapy and Broad Scope

Systematic Reviews

Results: 5 o.

A practical education.
hospital professionals atteractice courses for continuing to appraise internal validity in system

Rosati P, Porzsolt F.

J Eval Clin Pract. 2012 Jul 29; . Epub 2012 Jul 2

Cytotoxic T-lymphocyte associate polymorphisms and asthma ris

Nie W, Chen J, Xiu Q.

PLoS One. 2012; 7(7):e42062

Comparison of leukotriene rec addition to inhaled corticostero corticosteroid alone in the trea adolescents and adults with br meta-analysis.

Cao Y, Wang J, Bunjhoo H, Xie

Asian Pac J Allergy Immunol. 2012 Jun. 30(2):130-8.

Assessment of Airway Hyperresponsiveness: Comparison of Spirometry and Body Plethysmography.

Nensa F, Kotschy-Lang N, Smith HJ, Marek W, Merget R.

Adv Exp Med Biol. 2013: 755:1-9.

A Framework to Evaluate the Cultural Appropriateness of Intervention Research.

Crowder SJ, Broome ME.

West J Nurs Res. 2012 Jul 19; . Epub 2012 Jul 19.

See all (2527)

This column displays citations for systematic reviews, meta-analyses, reviews of clinical trials, evidence-based medicine, consensus development conferences, and guidelines. See filter information or additional related sources.

Results: 5 of 9644

Potential Association Between ANXA4 Polymorphisms and Aspirin-exacerbated Pespiratory Disease.

> JH, Bae JS, Park BL, Cheong HS, Uh ST, Kim MK, Choi IS, et

> > 5 2012

Change to Narrow Scope

environmental health research].

Schmidt B, Schulz C, Moebus S, Seiwert M, Kolossa-Gehring M, Jöckel KH.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Jun; 55(6-7):852-7.

Cytochrome c oxidase subunit 4 isoform 2-knockout mice show reduced enzyme activity, airway hyporeactivity, and lung pathology.

Hüttemann M, Lee I, Gao X, Pecina P, Pecinova A, Liu J, Aras S, Sommer N, Sanderson TH, Tost M, et al.

FASEB J. 2012 Jun 22; . Epub 2012 Jun 22.

Distribution of polymorphisms IL4-590 C/T and IL4 RP2 in the human populations of Madeira, Azores, Portugal, Cape Verde and Guinea-Bissau.

Berenguer AG, Câmara RA, Brehm AD, Oliveira S, Fernandes AT.

Int J Mol Epidemiol Genet. 2012; 3(2):179-83. Epub 2012 May 10.

See all (9644)

This column displays citations pertaining to topics in medical genetics. See more <u>filter information</u>.

PubMed Clinical Queries

Results of searches on this page are limited to specific clinical research areas. For compre

asthma

Clinical Study Categories

Category: Therapy

Scope: Narrow

Results: 5 of 7552

Psychosocial group intervention to enhance selfmanagement skills of people with dementia and their caregivers: study protocol for a randomized controlled trial.

Laakkonen ML, Hölttä EH, Savikko N, Strandberg TE. Suominen M. Pitkälä KH.

Trials. 2012 Aug 7; 13(1):133. Epub 2012 Aug 7.

Effects of Ionized Waterfall Aerosol on Pediatric Allergic Asthma.

Gaisberger M, Sanović R, Dobias H, Kolarž P, Moder A, Thalhamer J, Selimović A, Huttegger I, Ritter M, Hartl A.

J Asthma, 2012 Aug 6; . Epub 2012 Aug 6.

Effectiveness of magnesium sulfate as initial treatment of acute severe asthma in children. conducted in a tertiary-level university hospital: A randomized, controlled trial.

Torres S. Sticco N. Bosch JJ. Jolster T. Siaba A. Rocca Rivarola M. Schnitzler E.

Arch Argent Pediatr. 2012 Aug; 110(4):291-6.

MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebocontrolled trial of efficacy and safety.

Meltzer EO, Laforce C, Ratner P, Price D, Ginsberg D, Carr W.

Allergy Asthma Proc. 2012 Jul; 33(4):324-32.

Manipulating antioxidant intake in asthma: a randomized controlled trial.

Wood LG, Garg ML, Smart JM, Scott HA, Barker D, Gibson PG.

Am J Clin Nutr. 2012 Aug 1; . Epub 2012 Aug 1.

See all (7552)

This column displays citations filtered to a specific clinical study category and scope. These search filters were developed by Haynes RB et al. See more filter information.

Results: 5 of 2527

A practical educational tool for teaching child-care hospital professionals attending evidence-based practice courses for continuing medical education to appraise internal validity in systematic reviews. Rosati P. Porzsolt F.

J Eval Clin Pract. 2012 Jul 29: . Epub 2012 Jul 29.

Cytotoxic T-lymphocyte associated antigen 4 polymorphisms and asthma risk: a meta-analysis. Nie W, Chen J, Xiu Q.

PLoS One. 2012; 7(7):e42062. Epub 2012 Jul 26.

Comparison of leukotriene receptor antagonists in addition to inhaled corticosteroid and inhaled corticosteroid alone in the treatment of adolescents and adults with bronchial asthma: a meta-analysis.

Cao Y, Wang J, Bunjhoo H, Xie M, Xu Y, Fang H. Asian Pac J Allergy Immunol. 2012 Jun;

Assessment of Airway Hyperresponsiveness: Comparison of Spirometry and Body Plethysmography.

Nensa F, Kotschy-Lang N, Smith HJ, Marek W,

Adv Exp Med Biol. 2013; 755:1-9.

A Framework to Evaluate the Cultural Appropriateness of Intervention Research.

Crowder SJ, Broome ME.

West J Nurs Res. 2012 Jul 19; . Epub 2012 Jul

See all (2527)

This column displ

evidence-based medicine, consensus development conferences, and guidelines. See filter information or additional related sources.

Results for Therapy and Narrow Scope

Results: 5 of 9644

Potential Association Between ANXA4 Polymorphisms and Aspirin-exacerbated Respiratory Disease.

Park TJ, Kim JH, Bae JS, Park BL, Cheong HS, Pasaje CF, Park JS, Uh ST, Kim MK, Choi IS, et

Diagn Mol Pathol. 2012 Jul 27; . Epub 2012 Jul

Plasma and exhaled breath condensate nitritenitrate level in relation to environmental exposures in adults in the EGEA study.

Rava M, Varraso R, Decoster B, Huyvaert H, Le Moual N, Jacquemin B, Künzli N, Kauffmann F, Zerimech F. Matran R. et al.

Nitric Oxide. 2012 Jun 27; 27(3):169-175. Epub 2012 Jun 27.

[Concept for a German national birth cohort for environmental health research).

Schmidt B, Schulz C, Moebus S, Seiwert M, Kolossa-Gehring M, Jöckel KH.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2012 Jun: 55(6-7):852-7.

Cytochrome c oxidase subunit 4 isoform 2knockout mice show reduced enzyme activity. airway hyporeactivity, and lung pathology.


Hüttemann M, Lee I, Gao X, Pecina P, Pecinova


Click See all (7552)

See all (9644)

This column displays citations pertaining to topics in medical genetics. See more filter information.


Click Limits






Click | TTUHSC ONLINE

Ifor Free Full Text




When Searching from Off Campus:



Problems with eRaider call: 806-743-2870 or 806-743-2875







rch | My settings | My alerts

options...

PDF (923 K) More

Search ScienceDirect

9 Search



The American Journal of Medicine

Volume 123, Issue 4, April 2010, Pages 322-328.e2



Cited by in Scopus

Clinical research study

Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events

Shelley R. Salpeter, MD, FACP^{a, b, a, MD}, Andrew J. Wall, MD^{a, b}, Nicholas S. Buckley^C

- a Stanford University School of Medicine, Stanford, Calif.
- b Santa Clara Valley Medical Center, San Jose, Calif
- ^C California Institute for Technology, Pasadena

Available online 20 February 2010.

http://dx.doi.org/10.1016/j.amjmed.2009.07.035, How to Cite or Link Using DOI

Permissions & Referred to bySteven W. Yancey, Katharine Knobil, Kenneth Kral

No Association of Catastrophic Events with Advair

The American Journal of Medicine, Volume 123, Issue 10, October 2010, Page e15

₹ PDF (81 K)

Referred to by Aerik A. Williams, Shirley M. Fung, John R. Cohn

The Risk of Long-acting Beta-Agonists Revisited

The American Journal of Medicine, Volume 124, Issue 3, March 2011, Page e11



Abstract

Background

It is unclear whether long-acting β-agonists with concomitant inhaled corticosteroids increase asthma-related intubations and deaths. We pooled data on long-acting β-agonists with variable and concomitant inhaled corticosteroids to evaluate the risk for catastrophic asthma events.

Methods

We conducted searches of electronic databases, the US Food and Drug Administration website, clinical-trials registries, and selected references through December 2008. We analyzed randomized controlled trials in patients with asthma, which lasted at least 3 months, evaluated longacting β-agonists compared with placebo or long-acting β-agonists with inhaled corticosteroids compared with corticosteroids alone, and included at least 1 catastrophic event, defined as asthmarelated intubation or death.

Related articles

- Effect of high dose inhaled corticosteroids ...
- Allergologia et Immunopathologia Inhaled Corticosteroids
 –the FDA
- Takes Anot... Annals of Allergy, Asthma & Immunology
- Inhaled corticosteroids and severe viral inf...
- Journal of Allergy and Clinical Immunology Fluticasone propionate versus
- zafirlukast: e... Annals of Allergy, Asthma & Immunology
- Potential adverse effects of the inhaled Journal of Allergy and Clinical
- View more related articles

Table Download

Immunology

Find HTML data tables from the current article to download.

Find Tables

About Table Download



Most downloaded articles from the last three months in this journal:

- The DRESS Syndrome: A Literature
- Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment
- Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension
- View the most downloaded articles for The American Journal of Medicine



Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events

Shelley R. Salpeter, MD, FACP, a,b Andrew J. Wall, MD, a,b Nicholas S. Buckleyc

^aStanford University School of Medicine, Stanford, Calif; ^bSanta Clara Valley Medical Center, San Jose, Calif; ^cCalifornia Institute for Technology, Pasadena.

ABSTRACT

BACKGROUND: It is unclear whether long-acting β -agonists with concomitant inhaled corticosteroids increase asthma-related intubations and deaths. We pooled data on long-acting β -agonists with variable and concomitant inhaled corticosteroids to evaluate the risk for catastrophic asthma events.

METHODS: We conducted searches of electronic databases, the US Food and Drug Administration website, clinical-trials registries, and selected references through December 2008. We analyzed randomized controlled trials in patients with asthma, which lasted at least 3 months, evaluated long-acting β -agonists compared with placebo or long-acting β -agonists with inhaled corticosteroids compared with corticosteroids alone, and included at least 1 catastrophic event, defined as asthma-related intubation or death. RESULTS: In pooled trial data that included 36,588 participants, long-acting β -agonists increased catastrophic events 2-fold (Peto odds ratio [OR] 2.10; 95% confidence interval [CI], 1.37-3.22). Statistically significant increases were seen for long-acting β -agonists with variable corticosteroids compared with placebo (OR 1.83; 95% CI, 1.14-2.95) and for concomitant treatment with corticosteroids compared with corticosteroid alone (OR 3.65; 95% CI, 1.39-9.55). Similar increases in risk were seen for variable and concomitant corticosteroid use, salmeterol and formoterol, and children and adults. When the analysis was restricted to trials with controlled corticosteroid use, given as part of the study intervention, concomitant treatment still increased catastrophic events compared with corticosteroids alone (OR 8.19; 95% CI, 1.10.61 18).

CONCLUSION: Long-acting β -agonists increase the risk for asthma-related intubations and deaths, even when used in a controlled fashion with concomitant inhaled corticosteroids.

© 2010 Elsevier Inc. All rights reserved. • The American Journal of Medicine (2010) 123, 322-328

KEYWORDS: Asthma; Inhaled corticosteroids; Intubation; Long-acting beta-agonists; Meta-analysis; Mortality

There has been growing concern about asthma-related morbidity and mortality associated with the long-acting β -agonists salmeterol and formoterol, given with or without concomitant inhaled corticosteroids.¹⁻³ Pooled trial data have consistently shown that long-acting β -agonists, when given

Funding: Santa Clara Valley Medical Center, San Jose, Calif.

Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript. None of the authors have had any relationships with a pharmaceutical company that manufactures a β -agonist or other respiratory medications. Dr Salpeter has provided expert testimony on a litigation case involving a long-acting β -agonist and was paid on an hourly basis.

Authorship: All authors had access to the data and played a role in writing this manuscript.

Reprint requests should be addressed to Shelley Salpeter, MD, 751 S. Bascom Ave, San Jose, CA 95128.

E-mail address: salpeter@stanford.edu

with variable inhaled corticosteroid use, increase the risk for asthma-related hospitalizations, intubations, and deaths. $^{4-8}$ In July 2005 an advisory committee to the US Food and Drug Administration (FDA) concluded that Boxed Warnings of an increased risk for asthma-related mortality should be placed on all products containing long-acting β -agonists, with recommendations for treatment only after other asthma drues have failed. 1

The FDA subsequently requested data from sponsors of long-acting β -agonists (GlaxoSmithKline, Brentford, London, England; AstraZeneca, Wilmington, Del; and Novartis, Basel, Switzerland) on asthma-related intubations and deaths that occurred during published and unpublished randomized trials, as of January 2008. 9-11 Several meta-analyses have been performed, most with the cooperation or sponsorship of the pharmaceutical industry, which evalu-


Full Text

EMBASE

- * Major strength is drug-related information
- * Biomedical & pharmaceutical research literature
- * Contains article citations; over 80% include abstracts
- * International in scope; covers @5,000 journals
- * Compared to PubMed, 2,000 journals are unique
- * Updated daily









Main Search Page

Click EMTREE Tool



Log in I Register






Enter truvada








Expanded term list












						Help
Sear	ch Emtree Journals Authors					
Em	stree	Session Results	Clipboard	Saved Clipboards	Email Alerts	Saved Searches
[⊕ Query Builder					
	Build a multi-term search query					
	Find Term Browse by Facet					
	emtricitabine plus tenofovir disoproxil					
	Type word or phrase (without quotes)			Find Term		
	For term: 'emtricitabine plus tenofovir disoproxil'					
	Extend your search: 🗹 Explosion 🗆 As major focus					
	Take this query t	o Drug Search or	Add to Qu	uery Builder →		
	Emtree					
Ш	o chemicals and drugs					
П	agents affecting metabolism					
П	enzyme inhibitor					
П	transferase inhibitor					
П	nucleotidyltransferase inhibitor					
П	RNA directed DNA polymerase inhibitor	OO Dooredo				
	emtricitabine plus tenofovir disoproxil 🗅 1.4	38 Hecords				
	chemicals and drugs					
	antiinfective agent					
	antivirus agent					
	antiretrovirus agent					
	RNA directed DNA polymerase inhibitor					
	emtricitabine plus tenofovir disoproxil 🗓 1,438	Records				


EMTREE hierarchy
























Log in I Register



15 Results



Click View Full Text

antiretroviral treatment and tuberculosis: Can rifabutin fill the Loeliger A., Suthar A.B., Rix Glaziou P., O'Brien M., Renaud-Thery F., Crowley S., Williams B., Ridzon R., Granich R., Gilk International Journal of Tubero and Lung Disease 2012 16:1 (6-15) erms View Full Text □ Check Availability 6 Interventions to prevent sexually transm ections, including HIV infection Marrazzo J.M., Cates W. Clinical Infectious Diseases 2011 53:SUPPL. View Full Text □ Check Availability 7 Review article: Current antiviral therapy of chronic Avoub W.S., Keeffe E.B. Alimentary Pharmacology and Therapeutics 2011 34:10 (1145-1158)

OXFORD JOURNALS CONTACT US MY ACCOUNT MY BASKET

Clinical Infectious Diseases

ABOUT THIS JOURNAL CONTACT THIS JOURNAL SUBSCRIPTIONS

CURRENT ISSUE

Institution: Texas Tech University Health Sciences Center Library Sign In as Personal Subscriber

Oxford Journals > Medicine > Clinical Infectious Diseases > Volume 53, Issue suppl 3 > Pp. S64-S78.



National Immunization Awareness Month Supported by the IDSA

→

Click here for more...

Interventions to Prevent Sexually Transmitted Infections. **Including HIV Infection**

Jeanne M. Marrazzo1 and Willard Cates2

+ Author Affiliations

Correspondence: Jeanne M. Marrazzo, MD. MPH. Harborview Medical Center, Division of Infectious Diseases, 325 Ninth Ave, Mailbox 359932, Seattle, WA 98104 (imm2@uw.edu).

Abstract

The Centers for Disease Control and Prevention (CDC) Sexually Transmitted Disease (STD) Treatment Guidelines were last updated in

> on of the nce

« Previous | Next Article Table of Contents

This Article

Clin Infect Dis. (2011) 53 (suppl 3): S64-S78. doi: 10.1093/cid/cir695 This article appears in:

Sexually Transmitted Disease Treatment Guidelines

» Abstract

Full Text (HTML) Full Text (PDF)

Classifications

Supplement Articles

Search this journal:

Advanced »

Current Issue

September 1, 2012 55 (5)

GO



Click PDF



SUPPLEMENT ARTICLE

Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection

Jeanne M. Marrazzo1 and Willard Cates2

¹Department of Medicine, Division of Allergy and Infectious Diseases, University of Seattle; and ²FHI 360, Research Triangle Park, North Carolina

The Centers for Disease Control and Prevention (CDC) Sexually Transmitted Disease (STD) Treatment Guidelines were last updated in 2006. To update the "Clinical Guide to Prevention Services" section of the 2010 CDC STD Treatment Guidelines, we reviewed the recent science with reference to interventions designed to prevent acquisition of STDs, including human immunodeficiency virus (HIV) infection. Major interval developments include (1) licensure and uptake of immunization against genital human papillomavirus, (2) validation of male circumcision as a potent prevention tool against acquisition of HIV and some other sexually transmitted infections (STIs), (3) failure of a promising HIV vaccine candidate to afford protection against HIV acquisition, (4) encouragement about the use of antiretroviral agents as preexposure prophylaxis to reduce risk of HIV and herpes simplex virus acquisition, (5) enhanced emphasis on expedited partner management and rescreening for persons infected with Chlamydia trachomatis and Neisseria gonorrhoeae, (6) recognition that behavioral interventions will be needed to address a new trend of sexually transmitted hepatitis C among men who have sex with men, and (7) the availability of a modified female condom. A range of preventive interventions is needed to reduce the risks of acquiring STI, including HIV infection, among sexually active people, and a flexible approach targeted to specific populations should integrate combinations of biomedical, behavioral, and structural interventions. These would ideally involve an array of prevention contexts, including (1) communications and practices among sexual partners, (2) transactions between individual clients and their healthcare providers, and (3) comprehensive population-level strategies for prioritizing prevention research, ensuring accurate outcome assessment, and formulating health policy.

The landscape of interventions to prevent transmission of sexually transmitted infections (STIs), including human immunodeficiency virus (HIV) infection, has changed considerably since the Centers for Disease Control and Prevention (CDC) Sexually Transmitted Disease (STD) Treatment Guidelines were last updated in 2006 [1]. Major interval developments include

male circumcision as a potent prevention tool against acquisition of HIV and some STIs, (3) failure of a promising HIV vaccine candidate to afford protection against HIV acquisition, (4) encouragement about the use of antiretroviral agents as both early treatment for HIV-positive persons and preexposure prophylaxis for HIV-negative persons to reduce the risk of HIV and


Full Text Article

Gold Rush

- * Access to library subscribed e-journals
- Search by journal title







Mouse over eJournals

Click Gold Rush



Welcome to Gold Rush!



What is GoldRush?

GoldRush is similar to a library catalog for Journals. GoldRush knows about Publishers, Journal Titles, Volumes, Issues and Page Numbers. GoldRush **does not** know about article titles, keywords, concepts or topics.

Should I use GoldRush right now?

Use GoldRush when you already know everything about an article you wish to read (Publisher, Journal title, article title, publication year, volume, issue, page numbers) but you do not know where to find the article itself.

EXAMPLES:	If you are looking for	then search GoldRush for	
②	Journal of Prenatal Medicine 2011 Jul;5(3):69-77	Journal of Prenatal Medicine	
•	Anticancer Res 2000 Mar-Apr ;20(2A):853-9 PMID:10810366	Anticancer Research	
•	physical therapy for hip pain (topic)	Use GoldRush later. GoldRush does not know topics. GoldRush helps you find the location of an article only after you already have the following items from some other source: • Journal title • Article title • Volume • Issue • Page numbers First locate the items above using PubMed or another TTUHSC library database, then return to GoldRush to search for the location of your article.	
"Enlarging arachnoid cyst: a false alarm for infants" (article title)		Use GoldRush later. GoldRush does not know article titles. All GoldRush searches must begin with the Journal Title. First locate the title of the journal which published your article using PubMed or another TTUHSC library database, then return to GoldRush to search for the location of your article.	
Need help? Ask A Librarian			

Instructions for using

Enter

medical letter on drugs and therapeutics

EALTH SCIENCES CENTER Libraries of The Health Sciences

Gold Rus

Search by Journal Title

Browse Journals by Title (A-Z) GoldRush Self-Help

Ask a Librarian GoldRush Tutorial (PPT)

Exit

medical letter on drug

Search

Back to Results More Search Options

Welcome to



GoldRush is similar to a library catalog for Journals. GoldRush know GoldRush does not know about article titles, keywords, concepts o


Click

Search

bers.

Should I use

Use GoldRush when you already know everything about an article you wish to read (Publisher, Journal title, article title, publication year, volume, issue, page numbers) but you do not know where to find the article itself.



Trusted drug information and drug facts since 1959

Searcn:		Go
The Medica	al Letter Treatment Guideline	
· Disease Inde	x · Drug Index	Advanced Search

About Us

Subscriptions & Products

Contact Us

■ View Cart

Convolu

Wednesday, 08 August 2012

Licensed to

Texas Tech University



Products Include

The Medical Letter

Treatment Guidelines

Continuing Education

Mobile Apps



Antimicrobial Therapy

Drug Interactions



■ Join our mailing list

Welcome. You are now logged into The Medical Letter - Trusted Drug Information & Drug Facts Since 1959 as a member of Texas Tech University.

The Medical Letter

on Drugs and Therapeutics

The Medical Letter on Drugs and Therapeutics Objective, peer-reviewed evaluations of new FDAapproved drugs, and new information on previously approved drugs.

Current Issue

Browse Archives

August 6, 2012 (Issue 1396)

- PSA Reconsidered
- ► Ivermectin (Sklice) Topical Lotion for Head Lice
- ► Tablet Splitting
- ► In Brief: Truvada for HIV Prevention
- Addendaming what comes after medicinin for Type 2 Diabetes?

Current Issue: FULL TEXT | PDF

Coming Soon...

- Lorcaserin (Belviq) for Weight Loss
- ▶ Ezogabine (Potiga) for Epilepsy

Treatment Guidelines

from The Medical Letter®

Treatment Guidelines from The Medical Letter Unbiased reviews of drug classes used to treat common disorders. Includes the doses, adverse effects and the recommendations of expert reviewers.

Current Issue

Browse Archives

August 2012 (Issue 120)

Antifungal Drugs

The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious... [more]

Current Issue: FULL TEXT | PDF

Coming Soon...

- ▶ Drugs for Treatment of Chronic Heart Failure
- Antimicrobial Prophylaxis for Surgery



Trusted drug information and drug facts since 1959

Searcn:		 Go
○ The Me · Disease I	edical Letter O Treatme	Publications anced Search

About Us

Subscriptions & Products

Contact Us

■ View Cart

Wednesday, 08 August 2012

HOME: In Brief: Truvada for HIV Prevention

In Brief: Truvada for HIV Prevention

The Medical Letter on Drugs and Therapeutics • August 6, 2012 (Issue 1396) p. 63

Important Copyright Message: The Medical Letter® publications are protected by US and international copyright laws. For any distribution of this material is prohibited. Sharing a password with a non-subscriber or otherwise making the contents of t third parties is strictly prohibited. By accessing and reading the attached content I agree to comply with US and international these terms and conditions of The Medical Letter, Inc.

Truvada (Gilead), an oral fixed-dose combination of the antiretrovirals emtricitabine and tenofovir disoproxil fumarate frequent of HIV infection,1 has now also been approved by the FDA for pre-exposure prophylaxis to reduce the risk of sexually acquired risk. It is the first drug to be approved for this indication. The CDC has been recommending Truvada off-label for pre-exposure who have sex with men since 2011.2 A 30-day supply of Truvada costs about \$1160.3

Full Text

CLINICAL STUDIES — Approval for the new indication was based on 2 randomized, placebo-controlled trials in high-risk patien HIV-negative men (or transgender women) who have sex with men found that daily use of the combination reduced the risk of HIV seroconversion by 44% (36 seroconversions vs. 64 with placebo).4 A post-hoc analysis found that the rate of infection was reduced by 87.5% compared to placebo among men found to be adherent to the drug regimen (i.e., had detectable intracellular tenofovir levels). 5 The second trial included 4,747 heterosexual couples among whom one partner was HIV-infected and the other was not. Truvada reduced the risk of becoming infected by 75% (13 seroconversions vs. 52 with placebo).6

RECOMMENDATIONS — Pre-exposure prophylaxis with Truvada should be considered only for persons who are at high risk for HIV-1 acquisition, are confirmed to be HIV-negative and are willing to take the drug once daily and practice safer sex. Frequent follow-up HIV antibody testing is recommended while taking the drug to ensure early diagnosis of newly-acquired HIV infection; resistance to tenofovir/emtricitabine can develop if it is taken prophylactically by patients with HIV infection.

- 1. Drugs for HIV infection. Treat Guidel Med Lett 2011; 9:29.
- 2. Centers for Disease Control and Prevention (CDC). Interim quidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65.
- 3. Wholesale acquisition cost (WAC). Source: PricePointRx™. Reprinted with permission by FDB. All rights reserved. ©2012. http://www.firstdatabank.com/support/drug-pricing-policy.aspx. Accessed July 25, 2012. Actual retail price may be higher.
- 4. RM Grant et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587.
- 5. FDA. Background package for NDA 21-752/supplement 30. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteeMeetingMaterial.... Accessed July 25, 2012.
- 6. JM Baeten et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012 Jul 11 (epub).

This article has been freely provided.





Trusted drug information and drug facts since 1959

The Me	edical Letter	Treatment Drug Index		lications ed Search
		_		

About Us

Subscriptions & Products

Tech University.

Contact Us

■ View Cart

Welcome. You are now logged into The Medical Letter - Trusted Drug Information & Drug Facts Since 1959 as a member of Texas

Search:

Wednesday, 08 August 2012

Licensed to

Texas Tech University



Products Include

The Medical Letter

Treatment Guidelines

Continuing Education

Mobile Apps



Antimicrobial Therapy

Drug Interactions



■ Join our mailing list

The Medical Letter

on Drugs and Therapeutics

The Medical Letter on Drugs and Therapeutics Objective, peer-reviewed evaluations of new FDAapproved drugs, and new information on previously approved drugs.

Current Issue

Browse Archives

August 6, 2012 (Issue 1396)

- PSA Reconsidered
- ► Ivermectin (Sklice) Topical Lotion for Head Lice
- Tablet Splitting
- ► In Brief: Truvada for HIV Prevention
- ► Addendum: What Comes After Metformin for Type 2 Diabetes?

Current Issue: FULL TEXT | PDF

Coming Soon...

- Lorcaserin (Belviq) for Weight Loss
- ▶ Ezogabine (Potiga) for Epilepsy

Treatment Guidelines

from The Medical Letter®

Treatment Guidelines from The Medical Letter Unbiased reviews of drug classes used to treat common disorders. Includes the doses, adverse effects and the recommendations of expert reviewers.

Current Issue

Browse Archives

August 2012 (Issue 120)

Antifungal Drugs

The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious... [more]

Current Issue: FULL TEXT | PDF

Coming Soon...

- ► Drugs for Treatment of Chronic Heart Failure
- Antimicrobial Prophylaxis for Surgery



Subscriptions & Products

Trusted drug information and drug facts since 1959

Search:	Go
 ○ The Medical Letter ○ Treatment Guidelines ● All Public Disease Index • Drug Index Advance	olications ed Search

■ View Cart

HOME : Treatment Guidelines, Issue 120

Treatment Guidelines, Issue 120

Treatment Guidelines from The Medical Letter, August 1, 2012 (Issue 120)

- ▶ Download Issue 120 🏗
- ► Table of Contents 2012
- ► Take this CME exam

About Us

Full Text

Wednesday, 08 August 2012

Important Copyright Message: The Medical Letter® publications are protected by US and internation distribution of this material is prohibited. Sharing a password with a non-subscriber or otherwise making parties is strictly prohibited. By accessing and reading the attached content I agree to comply with US and international copyright law and these terms and conditions of The Medical Letter, Inc.

Contact Us

Antifungal Drugs

The drugs of choice for treatment of fungal infections are listed in the <u>table</u> that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious Diseases Society of America (<u>www.idsociety.org</u>). AZOLES Azole antifungal agents inhibit synthesis of ergosterol, an essential component of the fungal cell membrane. They vary in their spectrum of activity, oral bioavailability, adverse effects and potential for drug-drug interactions.

FLUCONAZOLE — Fluconazole (*Diflucan*, and others) is active against most *Candida* species other than *C. krusei*, which is intrinsically resistant, and many strains of *C. glabrata*, which are variably resistant. It has good activity against *Coccidioides* spp. and *Cryptococcus neoformans* and some activity against *Histoplasma capsulatum*. The drug has no clinically significant activity against most molds, including *Aspergillus* spp., *Fusarium* spp., and the Mucorales (formerly called Zygomycetes), such as *Mucor* spp. and *Rhizopus* spp..

Adverse Effects – Fluconazole is generally well tolerated. Headache, gastrointestinal distress, facial edema, rash and pruritus can occur. Stevens-Johnson syndrome, anaphylaxis, hepatic toxicity, leukopenia and hypokalemia have been reported. QT prolongation and torsades de pointes have also been reported.

Pregnancy – Fluconazole is teratogenic in animals. It is classified as pregnancy category C (risk cannot be ruled out) when used in a low dose (single dose of 150 mg) for vaginal candidiasis. It is classified as pregnancy category D (positive evidence of risk) when used for any other indication. Congenital abnormalities, including brachycephaly, cleft palate and congenital heart disease, have been reported in infants exposed in utero to high doses (400-800 mg/day) of fluconazole during most or all of the first trimester.2

Drug Interactions – Fluconazole is a strong inhibitor of CYP2C9 and 2C19 and a moderate inhibitor of CYP3A4; it can increase serum concentrations of drugs metabolized by these pathways. Concurrent use of fluconazole with other drugs known to prolong the QT interval, particularly those metabolized by CYP2C9, 2C19 or 3A4, may increase the risk of QT prolongation and torsades de pointes. 3 Taking fluconazole with the potent CYP enzyme inducer rifampin can reduce fluconazole serum concentrations, possibly to subtherapeutic levels.

Trusted drug information and drug facts since 1959

ocur ciii					GU
○ The Me	edical Lette	er Treatment	Guidelines	All Pub	lications
· Disease I	ndex	· Drug Index	1	Advance	d Search

About Us

Subscriptions & Products

Tech University.

Contact Us

■ View Cart

Welcome. You are now logged into The Medical Letter - Trusted Drug Information & Drug Facts Since 1959 as a member of Texas

Search:

Wednesday, 08 August 2012

Licensed to

Texas Tech University



Products Include

The Medical Letter

Treatment Guidelines

Continuing Education

Mobile Apps



Antimicrobial Therapy

Drug Interactions



■ Join our mailing list

The Medical Letter

on Drugs and Therapeutics

The Medical Letter on Drugs and Therapeutics Objective, peer-reviewed evaluations of new FDAapproved drugs, and new information on previously approved drugs.

Current Issue

Browse Archives

August 6, 2012 (Issue 1396)

- PSA Reconsidered
- ► Ivermectin (Sklice) Topical Lotion for Head Lice
- Tablet Splitting
- ► In Brief: Truvada for HIV Prevention
- ► Addendum: What Comes After Metformin for Type 2 Diabetes?

Current Issue: FULL TEXT | PDF

Coming Soon...

- Lorcaserin (Belviq) for Weight Loss
- ▶ Ezogabine (Potiga) for Epilepsy

Treatment Guidelines

from The Medical Letter®

Treatment Guidelines from The Medical Letter Unbiased reviews of drug classes used to treat common disorders. Includes the doses, adverse effects and the recommendations of expert reviewers.

Current Issue

Browse Archives

August 2012 (Issue 120)

Antifungal Drugs

The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious... [more]

Current Issue: FULL TEXT | PDF

Coming Soon...

- ▶ Drugs for Treatment of Chronic Heart Failure
- Antimicrobial Prophylaxis for Surgery



Subscriptions & Products

Trusted drug information and drug facts since 1959

Search: Go

The Medical Letter ○ Treatment Guidelines ● All Publications
Disease Index · Drug Index · Advanced Search

Contact Us

W View Cart

Wednesday, 08 August 2012

HOME: Mobile App Login for Site License users

About Us

for your device.

Mobile App Login for Site License users

The Medical Letter app is now available to download from the App Store or Android Market. It enables you to get the latest issue of **The Medical Letter on Drugs & Therapeutics** and **Treatment Guidelines from The Medical Letter** when and where you need it on your mobile device. **Drugs Past Issues of Dotti publications, find information simply by using our program of Disease Indexes, or simply search—an formation specifically.**

Fill out application

Required information	
-mail: *	
valid e-mail address is required.	
Confirm e-mail address: *	
Please re-type your e-mail address to confirm it is accurate.	
Password: *	
Confirm password: *	
Provide a password for the new login in both fields. Your password is case-sensitive.	
First Name: *	
ast Name: *	
Suffix:	
Ex: MD, RN, RPH)	
ATORIC -	
Additional:	
Sity: •	
State / Province: *	
Enter ZZ if no State/Province)	
Country: *	
tip code: *	
Phone Number:	
Please provide the primary number at which you are most likely to be reached. Enter your number using	
lyphens.	
Request Mobile App Login	

Other NLM Databases

RESEARCH TOOLS...

Maximum Simultaneous Use

Library Catalog

Textbooks

◆ Databases

eJournals


Online Multimedia

◆ Other Resources

LIBRARY SERVICES...


www.ttuhsc.edu/libraries

Click Databases









National Library of Medicine (NLM)

Source: National Library of Medicine (NLM) → (nep access)

Description: Searchable Web site with information health care professionals, researchers,

librarians, and publishers.

Note: Click here
→ for a list of NLM Databa
on the various TTUHSC Databases Web pa

National Library of Medicine classification

See: NLM classification

National Library of Medicine Drug Informa

See: Drug Information Portal

National Library of Medicine Gateway

See: NLM Gateway

Scroll and click National Library of Medicine





Click All NLM Databases & API's











Find, Read, Learn

Search biomedical literature Find medical terminologies Search NLM collections Read about diseases Learn about drugs **Explore history** Find a clinical trial Use a medical dictionary

Find free full-text articles

es from the History of torPlus

All NLM Databases & APIs

Summer 2012 Issue

NIH MedlinePlus the Magazine: Summer 2012

In this issue: prevent high cholesterol, avoid sleep-deprivation and improve your oral health.

Explore NLM

About NLM Health Information Library Catalog & Services History of Medicine Online Exhibitions & Digital Projects Information for Publishers Visit the Library

Research at NLM

Human Genome Resources Biomedical Research & Informatics Environmental Health & Toxicology Health Services Research & Public Health Health Information

NLM for You

Grants & Funding Meaningful Use Tools Training & Outreach Network of Medical Libraries Regional Activities Jobs at NLM Mobile Gallery

News & Events N

- NLM to Participate with Partners in "Shared Horizons: Data, Biomedicine, and the Digital Humanities" Symposium (08/06/12)
- Regenstrief and IHTSDO Start Collaborative Efforts [PDF] (07/31/12)
- NLM-Funded Investigator Creates First Complete Computerized Simulation of an Organism (07/31/12)
- NLM Hosts an Open Meeting of the Structured Product Labeling (SPL) Working Group Leadership Team (07/23/12)

Technical Bulletin



Connect with NLM



Technology

Multimedia Exhibition



Podcasts

& Widgets


NLM Tools

Copyright, Privacy, Accessibility, Site Map, Viewers and Players U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894

National Institutes of Health, Health & Human Services Freedom of Information Act, Contact Us



First published: 10 October 1993 Last updated: 07 August 2012 Permanence level: Permanent: Dynamic Content



GovDelivery, RSS, (HHS) resource providing information on HIV/AIDS Immunodeficiency Widgets Multilanguage clinical trials and federally approved HIV treatment Web 2.0 Syndrome and prevention guidelines. AIDSInfo API Provides access to the AIDSinfo drug database fact Acquired API sheets in XML format. The API returns information Immunodeficiency from both the professional and patient versions of Syndrome the AIDSinfo drug database fact sheets based on input query strings. AIDSInfo HIV/AIDS Glossary The AIDSinfo HIV/AIDS Glossary is a powerful tool Downloadable Files Reference Acquired that provides mobile access to over 850 pertinent Immunodeficiency (TXT, PDF), HIV/AIDS glossary terms in both English and Syndrome Mobile, Apps, Widgets Spanish.

ChemIDplus

ChemIDplus

- online dictionary
- chemicals, including names, synonyms, and chemical structures
- ChemIDplus Lite searches name or registry number
- Advanced ChemIDplus provides chemical structure, property, and toxicity searching

Enter aspirin and click search



ChemIDplus Lite

News

SIS H

▶Env. Health & Toxicol

J | About Us | Contact

OXNET ChemIDplus Lite

Select Database

 ChemIDplus ? ? HSDB ? TOXLINE ? CCRIS ? DART GENETOX ? ? IRIS ? ITER ? LactMed Multi-Database ? ? TRI ? Haz-Map

?

?

Household Products

TOXMAP

Search ChemiDplus

Search

Clear

Enter the name (e.g. formaldehyde) or registry number (e.g. 50-00-0) to search

Advanced ChemI Dplus Search

Provides chemical structure, property, and toxicity searching.

Env. Health & Toxicology



Portal to environmental health and toxicology resources

Support Pages

- ▶ Help
- ▶ ChemIDplus FAQ
- ▶ TOXNET Update Status
- Fact Sheet
- Database Description
- Training Manuals
- News



ChemIDplus Lite



Search

Navigation

Main Query Page

Advanced Cheml Dplus

Search

News

SIS Home

►Env. Health & Toxicology ►TOXNET ▶ChemIDplus Lite

Search Clear **ASPIRIN**

For more information about this substance.

Aspirin [BAN:JAN] RN: 50-78-2

Names

ClinicalTrials.gov

DART

DrugPortal

LiverTox

MeSH Heading

MeSH

Pillbox

RTECS

TOXLINE

Registry Numbers

Basic

Information

Full

Record

Synonyms

Formulas

Classification

Notes

Toxic ity

Physical Properties you may select from the links below.

File Locator

CCRIS

- i NCI Chem Carcino Res Info Sys
- i NIH ClinicalTrials.gov
- i Developmental and Reprod.Tox. DailyMed NLM/FDA Drug Labelling
 - NLM Drug Information Portal
- i EU Inv of Exist. Comm. Chem Sub **EINECS**
- EMIC i Env. Mutagen Info. Center i EPA GENetic TOXicology GENETOX
- **HSDB** i Hazardous Substances Data Bank
 - i Occ. Exposure to Haz. Agents
- Haz-Map LactMed i Drugs and Lactation Database
 - i Information on Drug-Induced Liver Injury
 - i Medical Subject Headings File
 - - Medical Subject Headings
- MedlinePlusAll i Search Consumer Health Info
- MedlinePlusDrug i Consumer Drug Information
 - i Drug Identification and Image Display
- PubChem PubChem
- PubMed i Biomedical Citations From PubMed
- PubMed AIDS i AIDS Citations from PubMed PubMed Cancer
 - i Cancer Citations from PubMed
- PubMed Toxicology i Toxicology Citations From PubMed
 - i Reg. of Toxic Eff. of Chem. Sub.
 - i NLM TOXLINE on TOXNET

Click Advanced ChemIDplus Search



ChemiDplus Advanced




News

SIS Home | Site | About Us | Contact | Help

▶Env. Health & Toxicology ▶TOXNET ▶ChemIDplus Lite ▶Advanced

Search Clear History He	elp
Substance Identification Name/Synonym Equals	P
Data is available for 394,462 records.	
Toxicity i	Э

	Toxic	ity 🗓		9
Test:	(any)	\$ b	etween	\$
			(mg/k	g or ppm)
Species:	(any)		‡	
Route:	(any)	‡		
Effect:	(any)			‡
Toxic	ity data is a	vailable for	139,354 red	ords.



Locator Codes i	9
(any) ‡	
AND ‡	
(any) ‡	

(any)		÷)	
Search	Clear	History	Help

D	ispl	lay	5	+	results

Structure i	Э			
Structure Search Ontions 1				
Structure Search Options Substructure Search				
Similarity Search 80 ÷ %				
Exact (parent only)				
Flex (parent, salts, mixture)				
Flexplus (parent, all variations)				
Display structures using i				
Marvin				
Structure data is available for 202 252 re	oorde			

Molecular Weight 🗓			
between	‡		
Molecular weig			
for 302.	252 record	ds.	

Display 5 + results

Search Options

Clinical Trials.gov



ClinicalTrials.gov is a registry and <u>results database</u> of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals. <u>Read more...</u>

Search for Clinical Trials

Find trials for a specific medical condition or other criteria in the ClinicalTrials.gov registry. ClinicalTrials.gov currently has 130,584 trials with locations in 179 countries.

Investigator Instructions

Get instructions for clinical trial investigators/sponsors about how to register trials in ClinicalTrials.gov. Learn about mandatory registration and results reporting requirements and US Public Law 110-85 (FDAAA).

Background Information

Learn about clinical trials and how to use ClinicalTrials.gov, or access other consumer health information from the US National Institutes of Health.

Resources:

Understanding Clinical Trials

What's New

Glossary

Study Topics:

List studies by Condition

List studies by Drug Intervention

List studies by Sponsor

List studies by Location



This site complies with the <u>HONcode standard</u> for trustworthy health information: <u>verify here</u>.

Contact Help Desk

Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine, U.S. National Institutes of Health, U.S. Department of Health & Human Services, USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act





DailyMed

Information

DailyMed provides high quality information about marketed drugs.

Drug labeling on this Web site is the most recent submitted to the Food and Drug Administration (FDA) and currently in use; it may include, for example, strengthened warnings undergoing FDA review or minor editorial changes. These labels have been reformatted to make them easier to read.

Options
Mome Home
E-mail Label Information
Downloads .
Archives
Notify of Updates
Contact Us
Help NEW
Web Services
Additional Resources
SPLIMAGE Specification NEW Version 3.0.2
Report Adverse Event
SPL Format Previewer
for Label Authors
Product Identification

At the present time this Web site does not contain a complete listing of labels for approved prescription drugs. Currently this Web site contains 39695 drugs.				
	Search:		GO	Advanced Search
意		Name	g Class O SetId	

Daily Med

About DailyMed

DailyMed provides high quality information about marketed drugs. This information includes FDA labels (package inserts). This Web site provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. The National Library of Medicine (NLM) provides this as a public service and does not accept advertisements.

Drug labeling and other information in the SPL is what has been most recently submitted by drug companies to the Food and Drug Administration (FDA) as drug listing information (See 21 CFR part 207). The drug labeling has been reformatted to make it easier to read but its content has not been altered or verified by FDA or National Library of Medicine. The drug labeling on this Web site may not be the labeling on currently distributed products or identical to the labeling that is approved. Drugs marked "OTC monograph final" or "OTC monograph not final" are not checked for conformance to the monograph. Drugs marked "unapproved" on this Web site have not been reviewed by FDA for safety and efficacy and their labeling has not been approved. For more information about unapproved drugs, visit Enforcement Activities by FDA.

Other information about drugs may also be available. NLM regularly processes data files uploaded from FDA's system and provides and maintains this Web site for the public to use in accessing the information. Additional information about medicines is available on NLM's MedlinePlus Web site http://www.nlm.nih.gov/medlineplus/medicines.html.



Copyright, Privacy, Accessibility

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health, Health & Human Services



We comply with the HONcode standard for health trustworthy information: verify here.

Dietary Supplements Labels Database



Dietary Supplements Labels Database brands, ingredients, and references

Advanced Search

About FAQ Glossary Recalls Related Resources Contact Help

Search

Products

- Men
- Women Seniors
- Kids/Teens

Active Ingredients

- All Ingredients
- Vitamins
- Minerals
- Herbs/Plants
- Amino Acids
- Enzymes
- Specialty

Manufacturers

All Manufacturers

he Dietary Supplements Labels Database offers information about label ingredients in more than 7,000 selected brands of dietary supplements. It enables users to compare label ingredients in different brands. Information is also provided on the "structure/function" claims made by manufacturers. These claims by manufacturers have not been evaluated by the Food and Drug Administration. Companies may not market as dietary supplements any products that are intended to diagnose, treat, cure or prevent any disease.

Ingredients of dietary supplements in this database are linked to other National Library of Medicine databases such as MedlinePlus® and PubMed® to allow users to understand the characteristics of ingredients and view the results of research pertaining to them, including the following characteristics:

- Uses in humans
- Adverse effects
- Mechanism of action

The Database can be searched by brand names, uses noted on product labels, specific active ingredients, and manufacturers.

Recalls from the U.S. Food and Drug Administration (FDA) and enforcement actions from the Federal Trade Commission (FTC) related to specific ingredients and supplement brands have also been provided.



Specialized Information Services | U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 | National Institutes of Health | Department of Health & Human Services Copyright | Privacy | Accessibility | Disclaimer | tehip@teh.nlm.nih.gov

Last updated: 1 June 2012

Drug Information

Contact NLM 9 Search

> The World's Largest Medical Library

Databases Find, Read, Learn Explore NLM Research at NLM NLM for You

Home > FAQs > FAQ: Reference & Consumer Health Questions

FAQ: Drug Information

Question: Where can I find information about drugs, including formulations and interactions?

Answer: We can only direct you to drug information resources. We encourage you to ask your doctor or pharmacist for drug information.

US Drug Information

The Drug Information Portal is a gateway to current drug information from the National Library of Medicine® (NLM) and other key government agencies.

http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp

More NLM tools to find drug information:

- MedlinePlus[®] <u>Drugs, Supplements, and Herbal Information</u> provides information about prescription drugs, over-the-counter medicines, dietary supplements, and herbal remedies. Includes side effects, dosage, special precautions, and more. http://www.nlm.nih.gov/medlineplus/druginformation.html
- DailyMed® provides information about prescription drugs as found in medication package inserts. http://dailymed.nlm.nih.gov/dailymed/about.cfm
- MEDLINE/PubMed or TOXLINE® provide citations to published biomedical journal research articles for professionals. For more information, see the MEDLINE® Fact Sheet at http://www.nlm.nih.gov/pubs/factsheets/medline.html and the TOXLINE® Fact Sheet at http://www.nlm.nih.gov/pubs/factsheets/toxlinfs.html
- DIRLINE® provides information about organizations dealing with drug information. http://dirline.nlm.nih.gov/

The Center for Drug Evaluation and Research (CDER) from the US Food and Drug Administration (FDA) has expertise to answer some drug information questions.

http://www.fda.gov/Drugs/default.htm

A CDER contact form is at http://www.accessdata.fda.gov/scripts/email/cder/comment.cfm or write to druginfo@fda.hhs.gov

FDA tools to find drug information, including formulations and interactions:

- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
- http://www.fda.gov/cder/orange/default.htm
- The Green Book: FDA Approved Animal Drug Products http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/UCM042847

International Drug Information

- British National Formulary (BNF) (free ONLY to residents of the UK and selected developing cour at http://www.bnf.org/bnf/extra/current/450070.htm http://www.bnf.org/bnf/index.htm
- International drug and food safety organizations, from the US Food and Drug Administration http://www.fda.gov/InternationalPrograms/default.htm
- European Medicines Agency from the European Union http://www.ema.europa.eu/ema/index.jsp
- Heads of Medicines Agencies can be searched by country for authorities in the European Union a Liechtenstein. http://www.hma.eu/index.html
- WHO Model Formulary from the World Health Organization

http://www.who.int/medicines/en/

Organizations

- American Society of Health-System Pharmacists (ASHP) http://www.ashp.org/
- International Pharmaceutical Federation (IPF) http://www.fip.org/www/index.php

- Pharmaceutical Research and Manufacturers of America (PhRMA) http://www.phrma.org/
- · International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) http://www.ifpma.org/

Additional Resources

- Contact your local public, hospital, or university library to ask what resources are available to you.
- Look for information on a drug company's Web site or on other sites such as Drug Digest, which includes drug interactions and drug comparisons at http://www.drugdigest.org/wps/portal/ddigest.
- · NLM does not maintain a list of gluten free drugs or foods. We suggest you check your pharmacy or the drug manufacturer for

NLM is not responsible for the availability or content of external sites, nor does NLM endorse, warrant, or quarantee the products, services or information described or offered at other sites.

Related Resource

Learn About Drugs - Drug Information from the National Library of Medicine

Return to top | Return to Reference & Consumer Health FAQs http://www.nlm.nih.gov/services/drug.html

Copyright, Privacy, Accessibility, Site Map, Viewers and Players U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health, Health & **Human Services**

Freedom of Information Act, Contact Us

USA.gov

Last reviewed: 14 July 2011 Last updated: 09 May 2012 First published: 01 January 1999 Metadata | Permanence level: Permanence Not Guaranteed

Drug Information Portal

Drug Information Portal

- gateway
- current, accurate drug information
- 33,368 drugs
- NLM and other key government agencies
- Mobile site

Drug Information Portal

Quick Access to Quality Drug Information



Home

News and Features **NLM Resources**

NLM Research Resources Resources by Audience / Class Other Resources

Mobile Site - NEW!





- ▶ Show examples.
- Show drug category descriptions.
- ▶ Show top "By Name" searches (previous seven days).
- ▶ Show top "By Category" searches (previous seven days).
- ▶ Show top dispensed prescriptions in the US Market, 2010.
- ▶ Show common drug name list.
- Show category name list.
- > Show list of resources searched.

Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
Drug Information Portal Mobile Site

Last updated: Aug 2012



Household Products Database



Household Products Database

National Institutes of Health National Library of Medicine Specialized Information Services



Ouick Search

Go Product, Manufacturer etc...

Advanced Search >

Browse by Category Auto Products Inside the Home **Pesticides** Landscape/Yard **Personal Care Home Maintenance** Arts & Crafts

Browse A-Z **Product Names Types of Products** Manufacturers Ingredients

Pet Care

Home Office

Support **About the Database** FAQ **Product Recalls** Help Glossary **Contact Us More Resources**

Health & Safety Information on Household Products

Home

Products

Manufacturers

Ingredients

Health Effects

What's under your kitchen sink, in your garage, in your bathroom, and on the shelves in your laundry room?

Learn more about what's in these products, about potential health effects, and about safety and handling.



Auto Products

Brake Fluid, De-icer, Lubricant, Sealant, and more...



Inside the Home

Air Freshener, Bleach, Cleaners, Toilet Bowl Cleaner, and more...



Pesticides

Animal Repellant, Fungicide, Herbicide, Insecticide, and more...



Landscape/Yard

Fertilizer, Lawn Care, Swimming Pool Products, and more...



Personal Care

Antiperspirant, Hair Spray, Makeup, Shampoo, Soap and more...



Home Maintenance

Caulk, Grout, Insulation, Paint, Putty, Stain, and more...



Arts & Crafts

Adhesive, Glaze, Glue, Primer, Varnish, and more...



Flea & Tick Control, Litter, Stain/Odor Remover, and more...



Home Office

Ink, Toner, Correction Fluid, Electronics Cleaners, Pens and more...

For advice if someone is poisoned, call your local Poison Center at 1-800-222-1222.

Home | Products | Manufacturers | Ingredients | Health Effects

Copyright, Privacy, Accessibility, Freedom of Information Act

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894

National Institutes of Health, Health & Human Services Customer Service: tehip@teh.nlm.nih.gov

Last updated: October, 2011

Product Menu

Go



Household Products Database

Home

Health & Safety Information on Household Products

National Institutes of Health National Library of Medicine Specialized Information Services

NLM

Quick Search

Product, Manufacturer etc...

Advanced Search

Browse by Category

Auto Products Inside the Home

Pesticides

Landscape/Yard

Personal Care

Home Maintenance

Arts & Crafts

Pet Care

Home Office

Browse A-Z

Products Names

Types of Products

Manufacturers

Ingredients

Support

About the Database

FAQ

Product Recalls

Help

Glossary

Contact Us

Products

Manufacturers Ingredients

Health Effects

Product Information

Product Name: Miracle Gro Garden Weed Preventer and Plant Food 9-17-9

EPA Registration 9198-149-623

Code:

Form: granules

Product Category: Pesticides » Herbicide » fertilizer w/weed control

Customer Service: 888-270-3714

Date Entered: 2001-05-30

Related Items: Products with similar usage in this database

Manufacturer

Manufacturer: Scotts Company

Address: 14111 Scottslawn Road

City: Marysville

State: OH

Zip Code: 43041

Telephone Number: 937-644-0011
Toll Free Number: 888-270-3714
Date Info Verified: 2009-03-06

Related Items: Products by this manufacturer

The following information (Health Effects, Handling/Disposal, and Ingredients) is taken from the product label and/or the Material Safety Data Sheet (MSDS) prepared by the manufacturer. The National Library of Medicine does not test products nor does it evaluate information from the product label or the MSDS. (What is an MSDS?)

Health Effects

Enter text or highlight term... Search TOXNET

Acute Health From MSDS

Effects: IMMEDIATE CONCERNS: May irritate eyes, nose, throat, and skin.

POTENTIAL HEALTH EFFECTS

EYES: May cause eye irritation.

SKIN: May cause skin irritation.

INGESTION: Ingestion may result in sore throat, abdominal pain, nausea, vomiting, and diarrhea. INHALATION: Dust may be irritating to the nose and respiratory tract, and may cause sore throat, coughing and shortness of breath.

ACUTE TOXICITY:

Signs and symptoms of overexposure might include headache, dizziness, fever, muscle aches, weakness, and other minor central nervous system effects.

MEDICAL CONDITIONS AGGRAVATED: Asthma and other pre-existing respiratory conditions; may increase the risk of angle-closure glaucoma.

ROUTES OF ENTRY: Ingestion, inhalation.

Chronic Health From MSDS

Effects: Asthma and other pre-existing respiratory conditions may be aggravated by exposure to this product; may increase the risk of angle-closure glaucoma.

Carcinogenicity: From MSDS

IARC: No NTP: No OSHA: No

GENERAL COMMENTS: Product may contain trace amounts of inorganic fluorides, which have been implicated as a reproductive hazard and a carcinogen.

First Aid: From MSDS

EYES: If in eyes, hold eye open and rinse slowly and gently with water for 15-20 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing. Call a poison control center or doctor for treatment advice.

SKIN: If on skin or clothing, take off contaminated clothing. Rinse skin immediately with plenty of water for 15-20 minutes. Call a poison control center or doctor for treatment advice.

INGESTION: If swallowed, call a poison control center or doctor immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to by the poison control center or doctor. Do not give anything by mouth to an unconscious person.

INHALATION: Move person to fresh air. If person is not breathing, call 911 or an ambulance, then give artificial respiration, preferably mouth-to-mouth, if possible. Call a poison control center or doctor for further treatment advice.

Health Rating: 2

Flammability 0

Rating:

Reactivity Rating: 0

HMIS Rating Scale: 0 = Minimal; 1 = Slight; 2 = Moderate; 3 =

Serious; 4 = Severe;

N = No information provided by manufacturer; * = Chronic Health Hazard

MSDS Date: 2000-11-14

Handling/Disposal

Handling: From MSDS

HANDLING:

See label. Avoid container breakage. Wash hands before eating, drinking, chewing gum, using tobacco or using toilet. Remove clothing immediately if product gets inside. Wash thoroughly and put on clean clothing. Keep out of lakes, streams, or ponds. KEEP OUT OF REACH OF CHILDREN.

STORAGE:

See label. KEEP OUT OF REACH OF CHILDREN.

Avoid container breakage. Keep container closed and away from food, feedstuffs, and domestic water supplies. Store in a cool, dry, well-ventilated area.

Do not reuse container and do not contaminate water by disposing of equipment washwaters.

ECOTOXICOLOGICAL INFORMATION: This pesticide is extremely toxic to freshwater marine and estuarine fish and aquatic invertebrates including shrimp and oyster. Do not apply directly to water. Do not apply in a manner which will directly expose canals, lakes, streams, ponds, marshes or estuaries to aerial drift. Do not contaminate water by disposing of equipment washwaters.


Disposal: From MSDS

DISPOSAL METHOD

Securely wrap original container in several layers of newspaper and discard in trash. Do not reuse bag.

Ingredients from MSDS/Label	
Chemical	CAS No / Unique Percent
<u>Urea</u>	000057-13-6
Trifluralin	001582-09-8
Potassium chloride	007447-40-7
Ammonium phosphate, monobasic	007722-76-1
Nuisance dust	999999-60-8

MedlinePlus



authoritative information for patients



A service of the U.S. National Library of Medicine NIH National Institutes of Health

Home About MedlinePlus Site Map FAQs Contact Us

Search MedlinePlus

Health Topics

Drugs & Supplements

& Cool Tools

ESPAÑOL

Drugs, Supplements, and Herbal Information



Drugs

Learn about your prescription drugs and over-the-counter medicines. Includes side effects, dosage, special precautions, and more.

Browse by generic or brand name

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

For FDA approved labels included in drug packages, see DailvMed.



Herbs and Supplements

Browse dietary supplements and herbal remedies to learn about their effectiveness, usual dosage, and drug interactions.

All herbs and supplements

Prescription and over-the-counter medication information is from AHFS® Consumer Medication Information, copyrighted by the American Society of Health-System Pharmacists (ASHP), Inc., Bethesda, Maryland; Copyright © 2012. All Rights Reserved.



Related Topics

AIDS Medicines Antibiotics Antidepressants **Blood Pressure Medicines Blood Thinners** Cancer Alternative Therapies Cancer Chemotherapy Cold and Cough Medicines Complementary and Alternative Medicine Diabetes Medicines **Dietary Supplements** Drug Safety Herbal Medicine Hormone Replacement Therapy Medicines Over-the-Counter Medicines Pain Relievers **Statins** Steroids Vitamins



Disclaimers Copyright Privacy Accessibility Quality Guidelines Viewers & Players

U.S. National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894 U.S. Department of Health and Human

Services National Institutes of Health

Page last updated on 18 April 2012

Click Drugs & Supplements

My Medication List



MyMedicationList



Launch MyMedicationList (beta)

About MyMedicationList

MyMedicationList is a prototype application developed at the National Library of Medicine that helps users manage their medication lists and make the records readily available when needed. This personal medication list can be printed out and serve as a reminder to the individual for taking medications, or as reference information to support continuity of care at providers' offices or hospitals.

Start MyMedicationList

Click on "Launch MyMedicationList" if the link is present: MyMedicationList will start; Othery Runtime Environment (JRE)". You will arrive at the Sun download homepage, browse to fin and install it (You will have to select your platform: Linux, Solaris or Windows). Then returnow should read "Launch MyMedicationList". Click on "Launch MyMedicationList" and MyMe can be downloaded here.

For Firefox users, open with Java Web Start Launcher.

For Netscape users on Windows, open with Javaws.exe. You might need to associate the file "JRE_HOME/javaws/javaws" (JRE_HOME is the directory that JRE is installed).

MyMedicationList code is digitally signed. You need to accept its security certificate to laun

MyMedicationList uses Java Web Start Technology and requires JRE 1.5 or later.

App to help users manage their medications


Secure User Environment

Different from Web-based systems in which patient information is stored by external databases, *MyMedicationList* is a standalone application that runs locally on users' computers. Users store medication lists just as they store any other files on their own computers. Medication lists are stored locally, typically on a hard drive or on a flash memory card. Users thus control access to their personal information and decide with whom to share it.



MyMedicationList





Correct/Complete Info Change Freq or Quantity Discontinue View Medication Guide Delete

Pillbox Beta





Home About FAQ Pill Images API Feedback

Two ways to identify an unknown pill



Quick Search (rapid identification, sort pills by color, shape, etc.)



Advanced Search (includes searching by drug name, inactive ingredients, and more)

What?

Pillbox enables rapid identification of unknown solid-dosage medications (tablets/capsules) based on physical characteristics and high-resolution images.

Once a medication is identified, Pillbox provides links to drug information and drug labels.

How?

Combining data derived from drug labels submitted to FDA by drug manufacturers and distributors and NLM's RxNorm, Pillbox is an identification and reference system for oral solid-dosage medications.


Pillbox's data and search engine are also available through an API.

National Library of Medicine National Institutes of Health U.S. Dept. of Health & Human Services Copyright Accessibility

Last updated: June 14, 2012

PubChem

Pub©hem




The PubChem BioAssay summary pages now display the Gene Ontology (GO) classification of the gene/protein target(s) that were tested by the bioassay.

In addition, the bioassay data summary for a compound now displays a graphical summary of the bioassays that have tested the compound, categorizing the bioassays by bioactivity outcomes, top targets, bioactivity types, and bioassay types. See more..

A new RESTful web interface to PubChem data and services (PUG REST) is released in beta form. See more..

more ...





Toxicology Data Network



TOXNET

Toxicology Data Network



TOXNET Mobile Access

SIS Home


About Us

Site Map & Search

▶ Env. Health & Toxicology ▶ TOXNET

TOXNET - Databases on toxicology, hazardous chemicals, environmental health, and toxic releases.

Select Database ? ChemIDplus ? HSDB TOXLINE ? CCRIS ? DART ? GENETOX ? ? IRIS ? ITER ? LactMed ? Multi-Database ? TRI ? Haz-Map ? Household Products ? TOXMAP



Search all databases: Enter term(s) in box above Search a specific database: Click database at left

Database description: Click on the 2

Env. Health & Toxicology



Support Pages


- Help
- ▶ TOXNET FAQ
- TOXNET Update Status
- Fact Sheet
- Database Description
- Training Manual & Schedule
 - News

Additional Resources

• CPDB	?
• CTD	?

Copyright, Privacy, Accessibility, FOIA

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health, Health & Human Services







SIS Home

About Us

Site Map & Search

SIS News

Contact Us

SIS Home > Environmental Health & Toxicology

TOXNET and Beyond Training Class Schedule and Workbook

Text size: S M L XL

Bookmark and

share

The workbook corresponds to the one-day class *TOXNET* and *Beyond:* Using the National Library of Medicine's Environmental Health and Toxicology Portal offered by the National Library of Medicine Training Center (NTC).

- Schedule
- Workbook (PDF, 8 MB)

PDF documents can be viewed with the free Adobe® Reader

Copyright, Privacy, Accessibility, FOIA

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894

National Institutes of Health, Health & Human Services

Last updated: 21 June 2011 First published: 21 April 2005

Metadata | Permanence level: Permanence Not Guaranteed

LactMed



TOXNET

Toxicology Data Network


TOXNET Mobile Access

SIS Home

About Us

Site Map & Search

Drugs and Lactation Database (LactMed) - A peer-reviewed and fully referenced database of drugs to which breastfeeding mothers may be exposed. Among the data included are maternal and infant levels of drugs, possible effects on breastfed infants and on lactation, and alternate drugs to consider.



Copyright, Privacy, Accessibility, FOIA

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894

National Institutes of Health, Health & Human Services

Drugs and Lactation Database LactMed Next Item Search Results

Download

Basic Search
Limits

Details

Browse Index

Other Files

Help

Modify Search

TOXNET NATIONAL LIBRARY OF MEDICINE

Contract all categories

Table of Contents Expand all categories

Select Clear

FULL RECORD

Drug Levels and Effects

Summary of Use during Lactat

Drug Levels

Effects in Breastfed Infants

Possible Effects on Lactation

Alternate Drugs to Consider

☐ References
☐ Substance Identification

Substance Name

CAS Registry Number

Drug Class

□ □ Administrative Information

LactMed Record Number

Last Revision Date

U.S. National Library of Medicine,
8600 Rockville Pike, Bethesda, MD 20894,
National Institutes of Health,
Department of Health & Human Services
Copyright and Privacy Policy,
Freedom of Information Act, Accessibility
Customer Service: tehip@teh.nlm.nih.gov
Download free Adobe® Reader.

Phenobarbital CASRN: 50-06-6

For other data, click on the Table of Contents

Drug Levels and Effects:

Summary of Use during Lactation:

There is a great deal of inter- and intrapatient variability in excretion of **phenobarbital** into breastmilk. **Phenobarbital** in breastmilk apparently can decrease withdrawal symptoms in infants who were exposed in utero, but it can also cause drowsiness in some infants, especially when used with other sedating drugs. If **phenobarbital** is required by the mother, it is not necessarily a reason to discontinue breastfeeding. Monitor the infant for drowsiness, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of psychotropic drugs. Sometimes breastfeeding might have to be limited or discontinued because of excessive drowsiness and poor weight gain. If there is concern, infant serum concentrations of **phenobarbital** can be obtained. Measurement of an infant serum level might help rule out toxicity if there is a concern.

NCBI

All Databases

Search

National Center for Biotechnology Information

NCBI Home

Resource List (A-Z)

All Resources

Chemicals & Bioassays

Data & Software

DNA & RNA

Domains & Structures

Genes & Expression

Genetics & Medicine

Genomes & Maps

Homology Literature

Proteins

Sequence Analysis

Taxonomy

Training & Tutorials

Variation

Welcome to NCBI

The National Center for Biotechnology Information advances science and health by providing access to biomedical and genomic information.

About the NCBI | Mission | Organization | Research | RSS Feeds

Get Started

- . Tools: Analyze data using NCBI software
- · Downloads: Get NCBI data or software
- . How-To's: Learn how to accomplish specific tasks at NCBI
- Submissions: Submit data to GenBank or other NCBI databases



dbVar archives large scale genomic variation data and associates defined variants with phenotypic information.

11 2 3 4 5 6 7

Popular Resources

PubMed

Bookshelf

PubMed Central

PubMed Health

BLAST

Nucleotide

Genome

SNP

Gene

Protein

PubChem

NCBI Announcements

New Microbial BLAST Page

28 Jun 2012

Now easier to use and with the familiar format and features of the

Sign up for the Fall Discovery Workshops!

12 Jun 2012

Registration is now available for the

NCBI's April Newsletter is on the Bookshelf

04 May 2012

Information about May's Discovery

More...

Plagiarism Resources

Click Guides & Tutorials

www.ttuhsc.edu/libraries Texas Tech University ▲ ▶ 🏠 🕒 🕮 🖾 🗡 http://www.ttuhsc.edu/libraries/ C Q- Google RESOURCES... **RESEARCH TOOLS...** About the Libraries Library Catalog Libraries Contact the Libraries Maximum Simultaneous Use Databases Ask A Librarian FACTS AT A GLANCE Audio Guides The TTUHSC Delia Montes-Gallo Library of El Paso serves the Paul L. Foster School of **♦ eJournals Guides & Tutorials** Medicine and the Gayle Greve Hunt School Distance Students ◆ Online Multimedia of Nursing. The Library also serves health professionals throughout the area, and on **EBM OSCE Instruction** the U.S. - Mexico border. HEALTH SCIENCES CENTER... ◆ Other Resources The library is located in two buildings: The LIBRARY SERVICES... Academic Education Center (AEC) houses HSC Home Clinical Sciences materials, while The ◆ Bibliographic Tools Welcome to the HSC Medical Education Building (MEB) houses ■ Downloads and Tools Basic Science materials. Office of the President ◀ Interlibrary Loan (ILL) Checkout privileges are available to TTUHSC Campuses faculty, staff and students. On-site use of the ◀ Reference Services Schools collection is also available to the public. Librarians @ Your Service HSC Info For **NEWS & ANNOUNCEMENTS...** Centers & Institutes PubMed eJournals Library Catalog Databases eBooks Research Ask A Librarian Administration Pub Med Off-campus Login (via eRaider) Human Resources Search: Mobile Resources Libraries Keywords MeSH Medline Plus □→ Accreditation The Daily Dose Popular resources by school TeamViewer 6 - Windows 🗈 **Emergency Preparedness** TeamViewer 6 - Mac □ Compliance Hotline NIH Clinical Alerts □ Allied Health Biomedical Medicine Nursing Pharmacy Library Cards We're social! SEARCH... FaceBook Twitter Outages Events

• general contacts • site map



CAMPUSES QUICK SEARCH INFO FOR SCHOOLS CONTACT INFO Home ▶ Libraries ▶ GO_P LIBRARY RESOURCES Guides & Tutorials Library Home About the Libraries ALTERNATIVE INFORMATION RESOURCES DURING A TTUHSC CAMPUS INTERNET OUTAGE Site Map Alternative Information Resources for Patrons

A Contact the Libraries Alternative Information Resources for TTUHSC Library Staff A Ask A Librarian **ABOUT THE TTUHSC LIBRARIES** Distance Students Harrington Library of the Health Sciences at Amarillo Detailed Guide ➡ Guides & Tutorials Quick Guide 🖂 Library Catalog Delia Montes-Gallo Library of the Health Sciences at El Paso Detailed Guide => Quick Guide 🖪 Databases Preston Smith Library of the Health Sciences at Lubbock Detailed Guide => Quick Guide A Gold Rush Library of the Health Sciences at Permian Basin Detailed Guide ➡ **Sharepoint Sites** Quick Guide 🖪 Library Services FAQ **HSC RESOURCES** Frequently Asked Questions -**HSC Home** COPYRIGHT AND PLAGIARISM Welcome to the HSC Copyright compliance
tutorial for faculty Office of the President Copyright compliance

tutorial for students (University of Texas' Copyright Crash Course)

Copyright compliance

tutorial for students (University of Texas' Copyright Crash Course) Campuses Schools

or contact us at:

Lubbock (806) 743-2200

Amarillo (806) 354-5448

El Paso (915) 545-6652

Odessa (432) 335-5171



Electronic Evaluations

The End